Antiemetics

• Chemoreceptor Trigger Zone (CTZ) and the Vomiting Center: The CTZ is located in the area postrema on the floor of the fourth ventricle, outside the blood-brain barrier, allowing direct sensing of emetogenic substances in blood and cerebrospinal fluid. The CTZ contains high densities of dopamine D2 receptors, serotonin 5-HT3 receptors, and substance P (neurokinin-1, NK1) receptors. Emetogenic stimuli (chemotherapy agents, opioids, radioactive materials) activate these receptors on CTZ neurons, which then project to the nucleus tractus solitarius and dorsal motor nucleus of the vagus—collectively termed the vomiting center—which orchestrates the motor act of vomiting through coordinated contraction of abdominal muscles, closure of the glottis, and relaxation of the gastric cardia.

• Serotonin (5-HT) Pathway: Chemotherapy agents, particularly platinum compounds and taxanes, cause direct mucosal injury to the small intestine epithelium, triggering massive release of serotonin (5-hydroxytryptamine) from enterochromaffin cells. This serotonin activates 5-HT3 receptors located on vagal afferent nerve terminals in the gut wall, transmitting emetogenic signals via the vagus nerve to the nucleus tractus solitarius. Additionally, 5-HT3 receptors are present on CTZ neurons themselves, allowing circulating serotonin to directly activate the chemoreceptor trigger zone. 5-HT3 antagonists (ondansetron, granisetron, palonosetron) block this critical pathway and are highly effective for chemotherapy-induced nausea and vomiting, particularly acute emesis occurring within 24 hours of drug administration.

• Substance P and Neurokinin-1 (NK1) Pathway: Substance P is a neuropeptide released in response to various emetogenic stimuli and acts through NK1 receptors located throughout the vomiting circuitry, including the chemoreceptor trigger zone, nucleus tractus solitarius, and higher cortical centers involved in anticipatory nausea. The NK1 pathway is particularly important in delayed emesis (occurring >24 hours after chemotherapy) and anticipatory nausea mediated by learned associations with prior chemotherapy. Aprepitant, a selective NK1 antagonist, crosses the blood-brain barrier and blocks substance P signaling, providing superior control of delayed CINV when combined with 5-HT3 antagonists and glucocorticoids.

• Dopamine Pathway: Dopamine released from CTZ neurons acts on D2 receptors in an autocrine/paracrine manner to facilitate emetogenic signaling. Additionally, metoclopramide functions as both a D2 antagonist (blocking CTZ activation) and a 5-HT3 antagonist (blocking vagal afferent signaling). The dopamine hypothesis explains why antipsychotics with D2-blocking activity (haloperidol, chlorpromazine) have antiemetic properties, though they are rarely used as first-line agents due to extrapyramidal side effects.

• Vestibular-Cerebellar Pathway: Motion sickness and vestibular vertigo trigger nausea through activation of the vestibular nucleus in the brainstem, which communicates with the vomiting center. Acetylcholine released from vestibular afferents activates muscarinic M1 receptors in the vomiting center. Anticholinergics (scopolamine, meclizine) block these muscarinic receptors and are highly effective for motion sickness and postoperative nausea related to positional changes during recovery.

• Histamine Pathway: Histamine-releasing mast cells in the gastrointestinal tract and central histamine in the vomiting center activate H1 receptors. First-generation antihistamines (diphenhydramine, meclizine) antagonize H1 receptors and provide antiemetic effects, with the added benefit of sedation that may reduce postoperative agitation. Their anticholinergic properties also contribute to antiemetic efficacy.

• Corticosteroid Mechanism: Glucocorticoids (dexamethasone, methylprednisolone) enhance antiemetic efficacy when combined with 5-HT3 antagonists and NK1 inhibitors through mechanisms that may involve inhibition of prostaglandin and cytokine production, enhancement of endogenous opioid signaling, or direct effects on neurotransmitter receptor expression in the vomiting center. The precise mechanism remains incompletely understood but is clinically highly important.

• Chemotherapy-Induced Nausea and Vomiting (CINV): The emetogenic potential of chemotherapy agents ranges from minimal to severe. Highly emetogenic agents (>90% incidence without prophylaxis) include platinum compounds (cisplatin, carboplatin), high-dose cyclophosphamide, dacarbazine, and mechlorethamine. Moderately emetogenic agents (30-90%) include doxorubicin, daunorubicin, and anthracyclines. The acute phase (0-24 hours) is primarily mediated by serotonin release from intestinal epithelial injury, while delayed emesis (>24 hours, peak at 48-72 hours) involves substance P and NK1 pathways. Patient risk factors for severe CINV include female sex, age <50 years, history of motion sickness or pregnancy-related nausea, prior chemotherapy exposure with nausea, and low alcohol consumption.

• Postoperative Nausea and Vomiting (PONV): PONV affects 20-30% of surgical patients, with higher incidence in gynecologic, abdominal, and strabismus surgery. The Apfel score identifies risk factors: female sex, nonsmoking status, history of PONV or motion sickness, and opioid use postoperatively. PONV is multifactorial, involving anesthetic agents (volatile anesthetics are more emetogenic than total intravenous anesthesia), surgical manipulation with vagal afferent activation, opioid administration, and patient movement during recovery.

• Medication-Induced Nausea and Vomiting: Opioids activate CTZ dopamine and serotonin pathways and also delay gastric emptying, leading to nausea in 20-30% of users. Antibiotics (macrolides, fluoroquinolones), digoxin, NSAIDs, and estrogen-containing oral contraceptives cause nausea through multiple mechanisms including direct gastric irritation, CTZ activation, and motion sickness (estrogen). Iron supplements cause nausea through direct gastric irritation. Chemotherapy agents (as discussed above) are the most emetogenic medications.

• Gastrointestinal Disorders: Gastroenteritis with viral or bacterial infection triggers nausea through vagal afferent activation from mucosal inflammation and direct serotonin release from infected enterocytes. Gastroparesis (diabetic, idiopathic, or postsurgical) causes nausea through gastric distention and delayed progression of food. Peptic ulcer disease, gastroesophageal reflux disease, and acute pancreatitis cause nausea through vagal and splanchnic afferent stimulation. Bowel obstruction triggers nausea through distention and altered intestinal motility.

• Vestibular and CNS Causes: Motion sickness, vertigo, migraine headaches, and increased intracranial pressure activate the vestibular system or directly stimulate the vomiting center. Vestibular causes are best managed with anticholinergics and antihistamines. CNS causes (trauma, tumors, infections) may require multiple antiemetic approaches.

• Metabolic and Systemic Causes: Hypercalcemia, uremia, diabetic ketoacidosis, and hepatic failure activate the CTZ through circulating metabolites. Hypoxia, hypercarbia, and pain also trigger nausea through CTZ activation and central sensitization.

• Nausea (Prodrome of Vomiting): Nausea represents the subjective, unpleasant sensation of impending vomiting mediated by ascending activation of the nucleus tractus solitarius and projections to higher cortical centers involved in conscious awareness. Patients typically describe a sick feeling, epigastric discomfort, or queasiness. Nausea may occur without progressing to vomiting and itself causes significant distress and functional impairment. In chemotherapy contexts, nausea may occur within minutes of drug administration (anticipatory nausea) or develop gradually over hours.

• Retching (Dry Heaves): Retching represents repetitive, rhythmic contractions of respiratory and abdominal muscles without actual expulsion of gastric contents, occurring when the stomach is empty or partially empty. Retching is mediated by the same vomiting center circuitry as vomiting and represents an incomplete motor response. Persistent retching is distressing and may progress to vomiting of bile or blood-tinged fluid if forceful.

• Vomiting (Emesis): Vomiting is the forceful expulsion of gastric and proximal duodenal contents through the mouth, coordinated by simultaneous relaxation of the gastric cardia, contraction of abdominal muscles and diaphragm, closure of the glottis, and contraction of the gastric fundus. Vomiting may be productive (containing food, bile, blood) or nonproductive (dry heaves). The character of vomitus provides diagnostic clues: bilious vomitus (green/yellow color) indicates small bowel or biliary involvement; coffee-ground appearance suggests hemorrhage; bloody vomitus (hematemesis) indicates mucosal bleeding from forceful retching (Mallory-Weiss tear) or underlying pathology.

• Timing and Triggers: In CINV, acute emesis typically peaks within 2-6 hours of chemotherapy administration, while delayed emesis develops 24-72 hours after treatment. Postoperative nausea typically emerges during recovery from anesthesia or within the first 24 hours postoperatively. Medication-related nausea often occurs with the first dose or after dose escalation. Motion-related nausea occurs with vestibular stimulation and may persist for hours after motion exposure. Anticipatory nausea in chemotherapy patients occurs before treatment administration based on learned association with prior emetogenic experiences.

• Associated Symptoms and Signs: Patients may experience epigastric discomfort, abdominal distention, cramping, and diaphoresis. Dehydration manifests as dry mucous membranes, reduced skin turgor, hypotension, tachycardia, and oliguria with concentrated urine. Aspiration risk is increased with altered consciousness or during vomiting episodes. Mallory-Weiss tears from forceful retching present with hematemesis and may require endoscopic intervention.

• Clinical Variants: Anticipatory nausea in chemotherapy patients is a learned phenomenon occurring before chemotherapy administration due to prior associations with nausea; this requires behavioral and psychological intervention in addition to pharmacotherapy. Cyclic vomiting syndrome represents recurrent episodes of severe nausea and vomiting separated by symptom-free intervals, often triggered by stress or illness, with unclear etiology but responsive to tricyclic antidepressants and topiramate. Cannabinoid hyperemesis syndrome occurs with chronic cannabis use and paradoxically causes intractable nausea and vomiting; discontinuation of cannabis is the only effective treatment, though haloperidol and benzodiazepines provide symptomatic relief.

• Clinical History: The timing of onset (acute vs. gradual), relationship to meals (postprandial nausea suggests gastroesophageal reflux or gastroparesis), association with medication administration, relationship to chemotherapy infusion, and frequency of emetic episodes guide differential diagnosis. The character of vomitus (bilious, bloody, undigested food) and presence of retching vs. productive vomiting help localize pathology. Associated symptoms (fever, diarrhea suggest infectious gastroenteritis; abdominal pain and distention suggest obstruction; vertigo suggests vestibular origin; headache suggests CNS pathology) guide workup.

• Physical Examination Findings: Assessment for dehydration status (orthostatic vital signs, skin turgor, mucous membrane moisture) evaluates severity. Abdominal examination for distention, firmness, visible peristalsis, abnormal bowel sounds (high-pitched, rushed sounds suggest obstruction), and focal tenderness localizes pathology. Neurologic examination including assessment of nystagmus, balance, and gait may reveal vestibular origin. Cranial nerve examination and fundoscopy assess for papilledema (elevated intracranial pressure). Examination of the oropharynx may reveal dental pathology or mucosal ulceration contributing to nausea.

• Laboratory Tests: Electrolyte panel assesses for hypokalemia, hypochloremia, hyponatremia, and acid-base disturbance (metabolic alkalosis from loss of gastric acid). Blood glucose evaluates for hyperglycemia or hypoglycemia as nausea cause. Liver function tests, bilirubin, and ammonia help exclude hepatic encephalopathy. Serum creatinine and BUN assess renal function and volume status. Complete blood count may reveal anemia (suggesting bleeding) or leukocytosis (suggesting infection). Thyroid stimulating hormone rules out hypothyroidism as nausea cause. Digoxin and other drug levels are checked if relevant.

• Imaging Studies: Abdominal radiographs (upright and supine) assess for bowel obstruction (air-fluid levels, dilated loops) or perforation (free air). Abdominal ultrasound or CT imaging evaluate for obstruction, perforation, acute pancreatitis, cholecystitis, or gastric outlet obstruction. Upper endoscopy (EGD) visualizes the esophagus, stomach, and duodenum to assess for ulcers, gastritis, malignancy, or anatomic abnormalities causing outlet obstruction. Gastric emptying study (scintigraphy with radiolabeled meal) quantifies gastric retention and diagnoses gastroparesis.

• Diagnostic Criteria and Severity Assessment: The Hesketh Classification categorizes chemotherapy agents by emetogenic potential: minimal risk (<10%), low risk (10-30%), moderate risk (30-90%), and high risk (>90%). The Apfel Score for PONV risk includes female sex, nonsmoking, history of PONV/motion sickness, and postoperative opioids, with score ≥2 indicating increased risk. For CINV, risk is assessed at each chemotherapy cycle, as prior experience and use of effective prophylaxis modify risk.

• Differential Diagnosis Considerations: Elevated intracranial pressure from any cause (tumor, hemorrhage, edema) presents with projectile vomiting without preceding nausea, more severe in morning, and associated with headache and neurologic signs. Migraine-associated nausea is prodromal, accompanying unilateral headache and photophobia. Cyclic vomiting syndrome presents with stereotyped episodes of severe nausea separated by symptom-free intervals. Gastropar

5-HT3 antagonists (ondansetron, granisetron, palonosetron)

• QT prolongation: blockade of the hERG (I_Kr) potassium channel delays repolarization and can precipitate torsades de pointes. The FDA withdrew the single 32 mg IV dose of ondansetron for this reason. Check ECG and correct hypokalemia/hypomagnesemia in patients on other QT-prolonging drugs; magnesium sulfate IV is the treatment for torsades.
• Headache and constipation: the most common effects; constipation reflects loss of 5-HT3–mediated enteric motility.
• Serotonin syndrome: rare, but risk rises with SSRIs, tramadol, linezolid, or MAO inhibitors.

Dopamine D2 antagonists (metoclopramide, prochlorperazine, promethazine, droperidol, haloperidol)

• Extrapyramidal symptoms: nigrostriatal D2 blockade causes acute dystonia (oculogyric crisis, torticollis), akathisia, and parkinsonism. Treat acute dystonia with an anticholinergic/antihistamine — IV diphenhydramine or benztropine; treat akathisia with a beta blocker (propranolol) or benzodiazepine.
• Tardive dyskinesia: metoclopramide carries an FDA boxed warning; treatment should generally not exceed 12 weeks. Often irreversible.
• Hyperprolactinemia: tuberoinfundibular D2 blockade → galactorrhea, gynecomastia, amenorrhea.
• Neuroleptic malignant syndrome: rare; stop the drug, cool, give dantrolene or bromocriptine.
• Contraindications: mechanical bowel obstruction or perforation (prokinesis worsens both), pheochromocytoma, seizure disorder, and Parkinson disease. Metoclopramide is renally cleared — reduce dose in CKD. Promethazine is contraindicated under age 2 (fatal respiratory depression) and carries a boxed warning for severe tissue injury/gangrene with extravasation. Droperidol carries a QT boxed warning. The AGS Beers Criteria list metoclopramide, promethazine, and scopolamine as potentially inappropriate in older adults.

Other classes

• Anticholinergics/antihistamines (scopolamine, meclizine, diphenhydramine): sedation, dry mouth, blurred vision, urinary retention, and anticholinergic delirium; avoid in narrow-angle glaucoma and BPH. Physostigmine reverses severe central antimuscarinic toxicity.
• Aprepitant: CYP3A4 inhibition raises dexamethasone levels (dose reduction required) and lowers oral contraceptive efficacy; fatigue and hiccups are typical.
• Dexamethasone: hyperglycemia, insomnia, and perineal burning with rapid IV push.

• Match the receptor to the pathway: chemotherapy and postoperative emesis are serotonergic/dopaminergic (5-HT3 and D2 blockers work); motion sickness is vestibular and cholinergic/histaminergic. Ondansetron does not treat motion sickness — this is the single most common distractor. The right answer there is a scopolamine patch (prophylaxis, applied before travel) or meclizine.
• Acute versus delayed CINV: acute (0–24 h) is serotonin-driven → 5-HT3 antagonist; delayed (peaks 48–72 h) is substance P–driven → NK1 antagonist (aprepitant). NCCN Antiemesis guidance for highly emetogenic regimens uses multi-drug prophylaxis combining an NK1 antagonist, a 5-HT3 antagonist, and dexamethasone, with olanzapine added.
• **Young patient develops torticollis, jaw spasm, or an oculogyric crisis hours after metoclopramide or prochlorperazine**: acute dystonia. Best next step is IV diphenhydramine (or benztropine), not more antiemetic.
• Metoclopramide is the classic "never" drug in two settings: mechanical bowel obstruction (prokinesis risks perforation) and Parkinson disease (D2 blockade worsens motor symptoms). For nausea in Parkinson disease, choose a 5-HT3 antagonist or trimethobenzamide.
• Metoclopramide is the FDA-approved agent for diabetic gastroparesis, but the boxed warning caps typical use at about 12 weeks because of tardive dyskinesia; the ACG gastroparesis guideline emphasizes the shortest effective course.
• Nausea and vomiting of pregnancy: per ACOG, first-line pharmacotherapy is doxylamine plus pyridoxine (vitamin B6); ondansetron and metoclopramide are later-line options.
• Prolonged QT on the ECG in a patient receiving ondansetron or droperidol is the association examiners test; check magnesium and potassium and avoid stacking QT-prolonging drugs.
• Cyclic vomiting in a chronic cannabis user relieved by hot showers is cannabinoid hyperemesis syndrome — standard antiemetics fail; cessation is definitive, with topical capsaicin or haloperidol for acute relief.